<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270643</url>
  </required_header>
  <id_info>
    <org_study_id>ViDiSAM</org_study_id>
    <nct_id>NCT04270643</nct_id>
  </id_info>
  <brief_title>Trial of High-Dose Vitamin D in the Treatment of Complicated Severe Acute Malnutrition</brief_title>
  <acronym>ViDiSAM</acronym>
  <official_title>Trial of High-Dose Vitamin D in the Treatment of Complicated Severe Acute Malnutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of the Punjab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind randomized placebo-controlled controlled trial will test the hypothesis
      that administration of high-dose oral vitamin D supplementation to children in Lahore,
      Pakistan, who are recovering from complicated severe acute malnutrition will safely
      accelerate weight gain (primary outcome) and enhance neurodevelopment, muscle mass
      accumulation, resolution of systemic inflammation and antimicrobial immune function
      (secondary outcomes).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean weight-for-height/length z-score</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean weight-for-height/length z-score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean weight-for-age z-score</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean height/length-for-age z-score</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean head circumference-for-age z-score</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean mid-upper arm circumference</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in overall and domain-specific (gross motor, fine motor, language and social) neurodevelopmental scores, Malawi Developmental Assessment Tool</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean fat mass index</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean fat-free mass index</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants experiencing relapse of severe acute malnutrition</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants readmitted to hospital due to any cause</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial immune function (concentrations of inflammatory mediators in supernatants of whole blood stimulated with lipo-polysaccharide, zymosan and heat-killed Salmonella typhi)</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of albumin, C-reactive protein, 25-hydroxyvitamin D, total alkaline phosphatase, parathyroid hormone, ferritin and hepcidin</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean haemoglobin concentration, full blood count</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume, full blood count</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular haemoglobin concentration, full blood count</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean neutrophil count, full blood count</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean lymphocyte count, full blood count</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean monocyte count, full blood count</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal concentrations of inflammatory markers (myeloperoxidase, neopterin and alpha-1 antitrypsin)</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal microbiome composition</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants dying</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse reactions</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Severe Acute Malnutrition</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two oral doses of 5 mg (200,000 international units) vitamin D3 in 1 ml ethyl oleate, given at baseline and two weeks thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two oral doses of 1 ml ethyl oleate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>ATC code A11CC05 (cholecalciferol)</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ethyl oleate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent of parent / guardian

          -  Age 6-59 months at enrolment

          -  Diagnosis of complicated SAM at the point of hospital admission as defined by the
             World Health Organisation.

          -  Medical team managing the child has made the decision to discharge the child from
             inpatient care

        Exclusion Criteria:

          -  Ingestion of a dose of vitamin D&gt;200,000 IU (5 mg) in the last 3 months

          -  Known diagnosis of primary hyperparathyroidism or sarcoidosis (i.e. conditions
             pre-disposing to vitamin D hypersensitivity)

          -  Known neurodevelopmental disorder (e.g. cerebral palsy)

          -  HIV infection

          -  Taking anti-tuberculosis treatment

          -  Inability to assess child's developmental status at baseline using the Malawi
             Development Assessment Tool

          -  Signs of rickets

          -  Corrected serum calcium concentration &gt;2.65 mmol/L on blood sample taken during the
             current hospital admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adrian R Martineau, MD PhD</last_name>
    <phone>+442078822511</phone>
    <email>a.martineau@qmul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javeria Saleem, MD PhD</last_name>
    <email>javeria.hasan@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Severe Acute Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD will be shared with other researchers subject to terms of Data Transfer Agreement and IRB approval</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2 years after completion of the trial</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

